US Sickle Cell Gene Therapy Contracting Demo Attracting Interest From States

The US Medicaid agency says states representing more than 80% of sickle cell patients are interested in a centralized contracting program, but House Republicans want legislation, not administrative interventions, to shape value-based payment for curative therapies.

sickle cell disease
The CMMI centralized contracting program is only focusing on sickle cell disease for now, Fowler said. • Source: Shutterstock

A US Medicaid program to test centralized contracting for sickle cell disease gene therapies has attracted widespread interest from state payors.

Key Takeaways

  • States are interested in a CMS program on centralized contracting for gene therapies treating sickle cell disease.

The US Center for Medicare and Medicaid Innovation has received letters of intent from “a majority of states that represent...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Medicare

CMS Should ‘Clarify’ That Part B Inflation Rebates Do Not Apply In Medicare Advantage, Pharma Urges

The Centers for Medicare and Medicaid Services is considering imposing price inflation rebates on Part B drugs furnished to enrollees in Medicare Advantage plans in addition to those covered by fee-for-service Medicare.

PS-MarketAccess (Premium-2): Why Financial Scammers Are So Successful Targeting Doctors

 
• By 

Doctors are increasingly falling victim to financial scams due to their high incomes, busy schedules, and trust in professional networks. Recognizing the tactics scammers use and the reasons behind physicians’ susceptibility is essential for protecting medical professionals.

PBM Legislation: Medicare Rebate Reform May Be Challenging Amid Disruption From Redesign

 
• By 

US lawmakers will undoubtedly continue to work on pharmacy benefit manager reform legislation in 2025, given its bipartisan support. But policies impacting rebates that could lead to higher premiums in Part D may be a tough sell in the midst of the benefit redesign.

Accelerated Approvals In Medicare: CED Guidance Notes Ongoing Concern With Surrogate Endpoints

 
• By 

Medicare coverage with evidence development final guidance includes few substantive changes from the proposed version despite biopharma stakeholder concerns.

More from Government Payers

PBMs and Vertical Integration: CBO Adds To Growing Concerns About Negative Impacts

 

Congressional Budget Office responses to questions from US lawmakers on pharmacy benefit managers could add to the momentum for PBM reforms to go further than the current leading proposals.

Pink Sheet Podcast: What We Learned From The First Batch Of Medicare Negotiated Drug Prices

 

Pink Sheet reporter and editors discuss the take-aways from the landmark first Medicare negotiated drug prices and what additional information remains outstanding.

A Better Deal: Medicare Discounts Surpass Estimated PBM-Negotiated Rebates

 
• By 

But the amount of savings realized when the Medicare negotiated prices go into effect in 2026 remains the subject of debate.